BioMarin Pharmaceutical (MEX:BMRN) Cyclically Adjusted Book per Share: MXN443.47 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
79 GF Score
Price MXN1,092.00
GF Value MXN1,321.11
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Cyclically Adjusted Book per Share?

BioMarin Pharmaceutical MEX:BMRN +13.87% 79 Cyclically Adjusted Book per Share is MXN443.47 as of Jun. 2026. GuruFocus rates MEX:BMRN with a GF Score™ of 79/100 and a GF Value™ of MXN1,321.11 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BioMarin Pharmaceutical's adjusted book value per share for the three months ended in Jun. 2026 was MXN567.228. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN443.47 for the trailing ten years ended in Jun. 2026.

During the past 12 months, BioMarin Pharmaceutical's average Cyclically Adjusted Book Growth Rate was 9.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 9.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 12.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BioMarin Pharmaceutical was 28.40% per year. The lowest was 9.30% per year. And the median was 17.00% per year.

As of today (2026-08-11), BioMarin Pharmaceutical's current stock price is MXN1092.00. BioMarin Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was MXN443.47. BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio of today is 2.46.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioMarin Pharmaceutical was 13.82. The lowest was 2.01. And the median was 5.44.


BioMarin Pharmaceutical  (MEX:BMRN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1092.00/443.47
=2.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioMarin Pharmaceutical was 13.82. The lowest was 2.01. And the median was 5.44.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BioMarin Pharmaceutical Cyclically Adjusted Book per Share Related Terms


BioMarin Pharmaceutical Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Cyclically Adjusted Book per Share Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 346.66 393.93 301.47 600.81 411.76

BioMarin Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 467.76 453.37 411.76 448.75 443.47

MEX:BMRN vs TECH, CYTK, SMMT: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio falls into.


MEX:BMRN
79GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioMarin Pharmaceutical's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=567.228/333.9520*333.9520
=567.228

Current CPI (Jun. 2026) = 333.9520.

BioMarin Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201609 297.954 241.428 412.141
201612 330.339 241.432 456.929
201703 300.854 243.801 412.102
201706 288.349 244.955 393.112
201709 290.951 246.819 393.664
201712 313.691 246.524 424.939
201803 288.682 249.554 386.313
201806 319.371 251.989 423.251
201809 306.482 252.439 405.446
201812 326.926 251.233 434.567
201903 318.180 254.202 418.002
201906 316.980 256.143 413.270
201909 337.937 256.759 439.536
201912 327.451 256.974 425.541
202003 420.280 258.115 543.763
202006 412.422 257.797 534.254
202009 493.435 260.280 633.101
202012 449.412 260.474 576.188
202103 465.732 264.877 587.186
202106 460.571 271.696 566.106
202109 477.867 274.310 581.767
202112 475.801 278.802 569.919
202203 472.875 287.504 549.271
202206 488.686 296.311 550.765
202209 494.531 296.808 556.419
202212 481.840 296.797 542.160
202303 447.648 301.836 495.279
202306 435.798 305.109 476.995
202309 452.899 307.789 491.397
202312 445.651 306.746 485.177
202403 443.712 312.332 474.426
202406 508.760 314.175 540.786
202409 559.376 315.301 592.465
202412 618.582 315.605 654.542
202503 618.097 319.799 645.451
202506 591.065 322.561 611.938
202509 578.376 324.800 594.673
202512 569.946 324.054 587.355
202603 579.612 330.213 586.175
202606 567.228 333.952 567.228

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN443.47 mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Cyclically Adjusted Book per Share of MXN443.47 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Cyclically Adjusted Book per Share too high?
BioMarin Pharmaceutical's current Cyclically Adjusted Book per Share is MXN443.47. Overall, BioMarin Pharmaceutical has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Cyclically Adjusted Book per Share compare to TECH and CYTK?
BioMarin Pharmaceutical's Cyclically Adjusted Book per Share of MXN443.47 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Cyclically Adjusted Book per Share is MXN443.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,321.11, compared to a current price of MXN1,092.00 — trading 17.3% below its estimated fair value. The current Cyclically Adjusted Book per Share is MXN443.47. BioMarin Pharmaceutical's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Cyclically Adjusted Book per Share is MXN443.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN1,092.00 is trading 17.3% below its estimated GF Value™ of MXN1,321.11. GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.

Key valuation signals for MEX:BMRN:

  • Cyclically Adjusted Book per Share: MXN443.47
  • GF Value™: MXN1,321.11 vs. price of MXN1,092.00 (17.3% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
79GF Score

Get the complete analysis for MEX:BMRN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,092.00
Price
MXN1,321.11
GF Value